Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 déc. 2019 16h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
09 déc. 2019 10h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

– Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years – – Cumulative Safety Profile (Core Period plus Extension...
09 déc. 2019 08h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

– Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse to Single Agent IDH1...
08 déc. 2019 09h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with...
02 déc. 2019 07h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
25 nov. 2019 07h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Jonathan Biller as Chief Legal Officer

CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
22 nov. 2019 16h00 HE | Source: Agios Pharmaceuticals, Inc.

Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

– Preliminary Efficacy Data Show 31% Overall Response Rate for Both Vorasidenib and TIBSOVO® with Postoperative Treatment – – Vorasidenib and TIBSOVO® Showed 2-HG Suppression of Greater Than 90% in...
13 nov. 2019 10h21 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced the closing of its previously announced underwritten public offering of common stock,...
07 nov. 2019 21h17 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Pricing of $256 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock...
06 nov. 2019 16h01 HE | Source: Agios Pharmaceuticals, Inc.

Agios Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million...

Page précédente

Page suivante